Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENV-294 in Healthy Adults and Adults With Moderate-To-Severe Atopic Dermatitis
NCT07336940Phase 1Completed
- Sponsor
- Enveda Biosciences
- Start
- Sep 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ENV-294 in atopic dermatitis (AD), sponsored by Enveda Biosciences. Primary endpoints: Safety and tolerability of ENV-294 at Day 42, Incidence of abnormalities in clinical chemistry parameters at Day 42 and 14 more. Started Sep 2025; status: completed.
02
Drugs
ENV-294
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07336940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07336940.